Considering that blocking the NLRP3 activation pathway alleviates chemotherapy-induced neuropathy [74] and that the dysregulation of NLRP3 inflammasome in some brain regions participates in the development of mood disorders [75], we hypothesized that the normalization of NLRP3 up-regulation and the inhibition of IL-1β, IL-6, and TNFα overexpression in the DRG and/or AMG might also take part in the inhibition of the allodynia and anxiodepressive-like behaviors which is caused by CoPP plus HRW during PTX-induced chemotherapy. The gene discussed is NLRP3; the disease is neuropathy.